Senti Biosciences, Inc.
SNTI evidence brief
What we can confirm
- Market Cap:
- $9.5M
What it means
What to watch
Prepared research question
What matters most for SNTI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SNTI
Senti Biosciences Holdings, Inc. (SNTI) is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform, with a lead program SENTI-202 in Phase 1 and a recent strategic transaction to separate its gene-circuit pipeline into a new entity [sec · filed 2026-09-10] [news · published 2026-07-15].
Key risk: Cash runway risk
Market Cap
$9.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Senti Biosciences, Inc..
Senti Biosciences Holdings, Inc. (SNTI) is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform, with a lead program SENTI-202 in Phase 1 and a recent strategic transaction to separate its gene-circuit pipeline into a new entity [sec · filed 2026-09-10] [news · published 2026-07-15].
- Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies [sec · filed 2026-09-10].
- As of June 30, 2026, the company reported cash and cash equivalents of $6.5 million, total revenue of $0.0 million, and a net loss of $12.8 million [sec].
- In July 2026, the company announced a strategic transaction to transfer its Gene-Circuit-enabled pipeline, including SENTI-202, to a new privately held company (NewCo) in exchange for a contingent value right (CVR) providing up to $60 million in milestone payments [news · published 2026-07-15].
- The company's lead product candidate, SENTI-202, is a logic-gated CAR NK cell therapy that entered Phase 1 clinical trials in April 2024 [catalyst].
- Shareholders' equity was negative $3.4 million as of June 30, 2026 [sec].
What works
- The company has a proprietary synthetic biology platform (gene circuits) designed to program cells with biological logic, which may enable differentiated next-generation cell and gene therapies [sec · filed 2026-09-10].
- SENTI-202, the lead candidate, has advanced to a Phase 1 clinical trial, indicating progress from preclinical to clinical development [catalyst].
- The strategic transaction with NewCo, backed by the company's largest investor, provides a potential pathway to unlock up to $60 million in milestone payments for SENTI-202 without immediate dilution [news · published 2026-07-15].
What to weigh
- The company has no revenue and reported a net loss of $12.8 million for the quarter ended June 30, 2026, with cash and equivalents of only $6.5 million [sec].
- Shareholders' equity is negative $3.4 million as of June 30, 2026, indicating accumulated deficits exceeding assets [sec].
- The company's partner Celest Therapeutics decided to stop dosing in its SN301A clinical trial in April 2025, raising uncertainty about that collaboration [sec_mda · as of 2026-03-27].
- The company acknowledges risks including limited management experience in running a public company and the need for additional financing to continue operations [sec · filed 2026-07-16] [sec_mda · as of 2026-03-27].
From the filings
Quoted directly from source documents.
Company description and platform
“We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases.”
SEC filings · September 10, 2026
Cash position as of June 30, 2026
“the Company estimates that its cash and cash equivalents were $6.5 million as of June 30, 2026.”
News · July 15, 2026
Strategic transaction with NewCo
“a newly formed privately held biotechnology company ("NewCo") controlled by affiliates of Celadon, the Company's largest investor, will acquire the Company's assets relating to its Gene-Circuit-enabled pipeline, including the rights to SENTI-202 in exchange for a contingent value right (a "CVR"), which will be distributed to equity holders providing up to $60 million in milestone payments”
News · July 15, 2026
Phase 1 start date for SENTI-202
“Phase1_Start: SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Malignancies”
Catalysts · April 22, 2024
Catalyst timeline
- 2024-04-22 · Phase 1 start for SENTI-202 — Initiation of the first clinical trial for the lead logic-gated CAR NK cell therapy candidate.
- 2026-07-15 · PDUFA for SENTI-202 — PDUFA date listed; however, the company announced a strategic transaction on the same date, so the regulatory status may be affected.
Risks & what to watch (4)›
Key risks
- Cash runway risk — With $6.5M cash and $12.8M quarterly net loss, the company may need additional financing within months [sec].
- Negative equity — Shareholders' equity of -$3.4M indicates liabilities exceed assets, raising going-concern risk [sec].
- Partner trial discontinuation — Celest Therapeutics stopped dosing in SN301A trial in April 2025, casting doubt on that collaboration [sec_mda · as of 2026-03-27].
- Limited public company experience — Management team has limited experience managing day-to-day operations of a public company [sec_mda · as of 2026-03-27].
What to watch
- Progress of SENTI-202 Phase 1 clinical trial and any data readouts [catalyst].
- Ability to secure additional financing after the strategic transaction with NewCo [news · published 2026-07-15].
- Milestone payments from NewCo tied to SENTI-202 development and commercialization [news · published 2026-07-15].
- Any updates on the Regulator Dial platform and retained assets [news · published 2026-07-15].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run Senti Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Senti Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 2.4%
- Days to cover
- 6.8
- Shares short
- 736,084
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SNTI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Senti Biosciences, Inc.?
Senti Biosciences Holdings, Inc. (SNTI) is a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform, with a lead program SENTI-202 in Phase 1 and a recent strategic transaction to separate its gene-circuit pipeline into a new entity [sec · filed 2026-09-10] [news · published 2026-07-15].
Who is the CEO of Senti Biosciences, Inc.?
Dr. Timothy K. Lu M.D., Ph.D. is the chief executive officer of Senti Biosciences, Inc. (SNTI).
Where is Senti Biosciences, Inc. headquartered?
Senti Biosciences, Inc. (SNTI) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Senti Biosciences, Inc. focus on?
Senti Biosciences, Inc. develops therapies across Oncology, Gene Therapy.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.